About Us

Nebulabio is a specialized contract research organization (CRO) at the forefront of in vitro antibody discovery. With deep-rooted expertise in single-chain variable fragment (scFv) biology and phage display technology, we provide targeted, high-performance screening services. Our team of dedicated scientists has successfully executed hundreds of scFv screening campaigns, consistently isolating high-affinity, functional binders against a diverse array of target classes, including complex membrane proteins, cytokines, and viral antigens. We partner with biotech and pharmaceutical clients globally to transform their target concepts into validated lead candidates with speed and precision.

☞Principle of scFv Phage Display Screening

scFv phage display is a refined application of the broader phage display platform, specifically leveraging the unique properties of the single-chain variable fragment format. The principle rests on the physical coupling of an scFv protein's function to its genetic code within a bacteriophage.

A library of billions of unique scFv genes is cloned into a phage vector, fused to a gene encoding a viral coat protein (typically the minor coat protein pIII of the M13 phage). When expressed in E. coli, each phage particle displays one unique scFv on its surface while packaging the corresponding gene inside its capsid. This direct genotype-to-phenotype link enables a powerful in vitro selection process called biopanning.

For scFvs, this format offers distinct screening advantages:

• Monovalent Display: Standard phagemid systems lead to monovalent scFv presentation, allowing for the true affinity-based selection of clones without avidity effects that can mask weaker but valuable interactions.

• Compact Size & Stability: The small, single-chain nature of scFvs can facilitate access to sterically restricted or concave epitopes that larger Fab or IgG formats might not reach efficiently.

• Direct Genetic Link: A positive binding signal from a phage particle directly leads to the scFv gene, enabling rapid sequence recovery and downstream cloning without additional steps.

The screening process exploits this link by iteratively selecting for phages that bind to an immobilized target antigen, amplifying them, and re-selecting over multiple rounds to enrich the population for the highest-affinity scFv clones.

Figure 1. Antibody model showing subunit composition and domain distribution along the polypeptide chains. Single-chain fragment variable (scFv) antibody generated by recombinant antibody technology appears in the shaded area.

☞Overview of Our scFv Antibody Screening Workflow

Our service delivers a complete, start-to-finish screening campaign designed for maximum success with scFv libraries. We tailor each step to the specific characteristics of your target and library.

 Phase 1: Project Initiation & Target Immobilization 

We begin with a detailed consultation to define screening objectives, stringency, and library choice (custom or pre-made). Our experts then prepare and validate your antigen in the optimal format for panning—whether coated on plates, biotinylated for solution-phase capture, or presented on cell surfaces.

 Phase 2: Iterative Biopanning (The Selection Engine) 

The scFv phage library undergoes 3-5 rounds of our optimized panning protocol. Each round consists of:

• Binding: Incubation of the library with the target.

• Stringent Washing: Removal of non-specific and weak binders; stringency increases each round.

• Elution: Recovery of specifically bound scFv-phage particles.

• Amplification: Infection of E. coli with eluted phages to produce an enriched pool for the next round.

We monitor enrichment after each round via phage ELISA to ensure effective selection.

 Phase 3: Monoclonal Analysis & Hit Identification 

Individual bacterial clones from the final enriched output are picked. The clones are screened for target binding using monoclonal phage ELISA. All positive clones are sequenced, and the sequences are analyzed bioinformatically to group them into families based on CDR homology, identifying unique leads versus clones derived from the same parent.

 Phase 4: Soluble Expression & Primary Characterization 

The variable region genes of unique lead scFvs are subcloned into an expression vector for soluble production in E. coli (periplasmic or cytoplasmic). Purified scFvs undergo primary validation:

• Binding Confirmation: ELISA to confirm specificity.

• Affinity Assessment: Preliminary kinetics via Octet BLI (Biolayer Interferometry).

• Cross-Reactivity Check: Testing against related proteins to assess specificity.

 Phase 5: Reporting & Delivery 

You receive a comprehensive project report with all data, including enrichment curves, ELISA results, sequence alignments, affinity rankings, and detailed protocols. Deliverables include all unique scFv sequences, expression plasmids, and optionally, purified scFv proteins.

 Screening Process Flowchart：

☞Applications of scFv Phage Display Screening

Our scFv screening service is a key enabling technology for numerous advanced applications:

• Therapeutic Lead Discovery: Direct isolation of human or humanized scFv leads against novel targets for oncology, autoimmune, and infectious diseases.

• CAR-T Cell Targeting Domain Discovery: scFvs are the preferred antigen-binding module for Chimeric Antigen Receptors. We screen libraries to find optimal, specific scFvs against tumor-associated antigens for next-generation cell therapies.

• Bispecific & Multispecific Antibody Engineering: scFvs serve as ideal, modular building blocks. Screening yields individual "arms" that can be assembled into bispecific formats like T-cell engagers.

• Diagnostic & Imaging Reagent Development: Selection of highly specific scFv pairs for ELISA development or stable, small-sized binders for in vivo imaging probes.

• Intracellular Antibodies (Intrabodies): Screening for scFvs that fold and function in the reducing cytoplasm, enabling intracellular target modulation for research and potential therapy.

• Affinity Maturation: Improving the binding strength of an existing antibody by screening focused mutagenesis libraries of its scFv format.

• Epitope Binning & Mapping: Using panels of selected scFvs to map binding sites on a target antigen, crucial for understanding mechanism of action and IP strategy.

☞Why Choose Us for Your scFv Phage Display Screening?

• scFv-Specific Expertise: Our protocols are optimized specifically for the folding, stability, and monovalent display characteristics of scFvs, leading to higher rates of functional hit recovery.

• Proven Success with Diverse Targets: We have a documented track record of successfully isolating scFvs against notoriously difficult targets like GPCRs, ion channels, and other multi-pass membrane proteins.

• Tailored Panning Strategies: We don't employ a one-size-fits-all approach. We design panning campaigns with the appropriate strategy—solid-phase, solution-phase, or cell-based—based on your target's biology.

• Integrated Bioinformatics: Our workflow includes advanced sequence analysis and clustering, allowing us to identify truly unique leads and provide insights into the selected antibody repertoire's diversity.

• Focus on Developability: During our analysis, we screen scFv sequences for potential developability issues (e.g., aggregation propensity, unusual residues) early on, helping you select the most promising leads for further development.

• End-to-End Project Management: You are assigned a dedicated project scientist who manages your screening campaign from start to finish, ensuring clear communication, timely updates, and expert interpretation of results.

• Speed and Confidentiality: We deliver high-quality data within a clear timeline (typically 10-14 weeks for a full campaign) under strict confidentiality and IP protection agreements.

Accelerate your therapeutic or reagent discovery program with Nebulabio’s specialized scFv screening expertise. Contact us to discuss your target and develop a winning screening strategy.